The estimated Net Worth of Life Sciences Ix, L.P.Fhmls... is at least $3.86 Milion dollars as of 3 March 2020. Life Fhmls owns over 550,000 units of Passage Bio Inc stock worth over $3,857,099 and over the last 5 years Life sold PASG stock worth over $0.
Sign up
Life Fhmls PASG stock SEC Form 4 insiders trading
Life has made over 2 trades of the Passage Bio Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Life bought 550,000 units of PASG stock worth $9,900,000 on 3 March 2020.
The largest trade Life's ever made was buying 550,000 units of Passage Bio Inc stock on 3 March 2020 worth over $9,900,000. On average, Life trades about 500,000 units every 113 days since 2019. As of 3 March 2020 Life still owns at least 5,009,219 units of Passage Bio Inc stock.
You can see the complete history of Life Fhmls stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Passage Bio Inc
Over the last 5 years, insiders at Passage Bio Inc have traded over $535,533 worth of Passage Bio Inc stock and bought 4,392,148 units worth $41,339,284 . The most active insiders traders include Liam Ratcliffe, Advisors Llc Orbi Med Capit... oraz Thomas Woiwode. On average, Passage Bio Inc executives and independent directors trade stock every 37 days with the average trade being worth of $92,858. The most recent stock trade was executed by Kathleen Borthwick on 10 February 2024, trading 4,000 units of PASG stock currently worth $3,080.
What does Passage Bio Inc do?
passage bio, inc., a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (cns) diseases. the company develops pbgm01, which utilizes a proprietary, aavhu68 capsid to deliver to the brain and peripheral tissues a functional glb1 gene encoding lysosomal acid beta-galactosidase (ã-gal) for infantile gm1; pbft02, which utilizes an aav1 capsid to deliver to the brain a functional granulin, or grn, gene encoding progranulin for the treatment of ftd caused by a deficiency of progranulin; and pbkr03, which utilizes a proprietary, aavhu68 capsid to deliver to the brain and peripheral tissues a functional galc gene encoding the hydrolytic enzyme galactosylceramidase, for infantile krabbe disease. it has a strategic research collaboration with the trustees of the university of pennsylvania's gene therapy program; and collaboration agreement, and a development services and clinical supply agreement with catalent maryland, inc. the company was fou
What does Passage Bio Inc's logo look like?
Complete history of Life Fhmls stock trades at Mirum Pharmaceuticals Inc i Passage Bio Inc
Passage Bio Inc executives and stock owners
Passage Bio Inc executives and other stock owners filed with the SEC include:
-
Dr. Bruce A. Goldsmith M.B.A., Ph.D.,
CEO, Pres & Director -
Dr. Maxine Gowen M.B.A., Ph.D.,
Interim Exec. Chairwoman -
Desiree Luthman D.D.S.,
Sr. VP of Global Regulatory Affairs -
Dr. Mark Forman M.D., Ph.D.,
Chief Medical Officer -
Monika Tornsen,
Chief Commercial Officer -
Gregory Fuest,
VP of Global Commercial Strategy & Marketing -
Alexandros Fotopoulos MBA, MSc,
Chief Technical Officer -
Monika Maria Tornsen,
Chief Commercial Officer -
Dr. Eliseo Oreste Salinas M.D., M.Sc.,
Chief R&D Officer -
Robin DeRogatis M.B.A.,
Sr. VP HR -
Gwen Fisher M.B.A.,
VP of Corp. Communications -
Edgar B. Cale Esq., J.D.,
Gen. Counsel & Company Sec. -
Stuart M. Henderson,
VP Investor Relations & Strategic Fin. -
Alexandros Fotopoulos MSc, MBA,
Chief Technical Officer -
Simona King,
CFO & Corp. Sec. -
Dr. James M. Wilson M.D., Ph.D.,
Co-Founder & Chief Scientific Advisor -
Bruce A Goldsmith,
CEO and President -
Life Sciences Ix, L.P.Fhmls...,
-
Venture Capital Vi, L.P.Ver...,
-
Advisors Llc Orbi Med Capit...,
-
Eliseo Oreste Salinas,
Chief Res. & Develop Officer -
Mark S Forman,
CHIEF MEDICAL OFFICER -
Monika Maria Toernsen,
Chief Commercial Officer -
Stephen P Squinto,
Head of Research and Dev -
Jill M. Quigley,
Chief Operating Officer -
Richard Steven Morris,
Chief Financial Officer -
Gary Romano,
Chief Medical Officer -
Patrick J Heron,
Director -
Liam Ratcliffe,
Director -
Thomas Woiwode,
Director -
Tadataka Yamada,
Director -
Edgar B. Cale,
GC & CORPORATE SECRETARY -
Kathleen Borthwick,
CFO -
Derrell Porter,
-
Simona King,
Chief Financial Officer -
Saqib Islam,
-
Dolan Sondhi,
-
Maxine Gowen,
-
Sandip Kapadia,
-
Athena Countouriotis,
-
Michael E. Kamarck,
Director -
William Chou,
PRESIDENT AND CEO